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Abstract: Ample evidence indicated that hematopoietic stem cells (HSCs) receive signaling from infection or other 
immune responses to adjust their differentiation and self-renewal. More recent reports also suggested that, while 
the bone marrow microenvironment or niche may provide the immune privilege for HSCs, HSCs can present surface 
immune inhibitors per se to suppress innate immunity and adaptive immunity to evade potential immune surveil-
lance and attack. These findings support the hypothesis that HSCs are capable of interacting with the immune 
system as signal “receivers” and signal “providers”. On the one hand, HSCs are capable of directly sensing the 
signals from the immune system through their surface receptors to modulate their self-renewal and differentiation 
(“in” signaling); on the other hand, HSCs display surface immune inhibitory molecules to evade the attack from the 
innate and adaptive immune systems (“out” signaling). The continuing investigation of the interplay between HSCs 
and immunity may lead to the open-up of a new research filed – the immunology of stem cells.
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Introduction
Hematopoietic stem cells (HSCs) are responsi-
ble for the daily production of all the lineages of 
blood cells in the body and have been widely 
used in transplantation to treat patients with 
leukemia, lymphoma, some solid cancers, and 
autoimmune diseases [1]. The balance between 
different cell fates—quiescence, self-renewal, 
differentiation, apoptosis, and migration—
determines the number and function of HSCs 
[1]. In nature HSCs are an essential part of the 
immune system by production of different 
types of immune cells. The bone marrow micro-
environment or niche provides an immune-priv-
ileged site for HSCs [2]. This is opposite to the 
situation of pluripotent stem cells, which are 
not immune privileged [3, 4]. Deeper than that, 
recent evidence suggests that HSCs per se 
express surface molecules mediating “in” sig-
naling and “out” signaling that directly dialogs 
with the immune system. For the “in” signaling, 
the stimulatory signals originated from infec-
tion and inflammation activate HSCs and 
induce differentiation through surface recep-
tors including toll-like receptors (TLRs), tumor 
necrosis factor α (TNFα) receptor, interferon 
(IFN) receptors, and others (see review by 
Goodell’s group [5]). Our most recent study also 
suggests that there exists inhibitory “in” signal-
ing that decreases differentiation and potential 
exhaustion of stemness of HSCs so that the 
stem cell potential is reserved [6]. On the other 
hand, the “out” signaling, mediated by surface 
immune inhibitory molecules such as CD47 and 
CD274, inhibits attack from the innate and 
adaptive immune responses, respectively [7, 
8]. The “out” signaling enables HSCs to gain 
regulatable “immune privilege” that is to a cer-
tain extent similar to that of mesenchymal stem 
cells and amnion stem cells [9]. We propose 
that the co-existence of both types of signaling 
ensures the balance of cell fates of HSCs. This 
review focuses on recent progress suggesting 
how HSCs interact with the immune system 
through these “in” and “out” signaling.
“In” signaling
HSC activation by the immune system through 
stimulatory receptors: While HSCs are resistant 
to direct infection by pathogens ([10-12]; we 
HSCs and immunity
220 Am J Blood Res 2012;2(4):219-227
speculate that the “out” signaling of HSCs may 
prevent these cells from direct infection, see 
below), it is also clear that HSCs can directly 
respond to pathogen-specific infection through 
systematic cytokine stimulation from both 
innate and adaptive immune signals. Several 
classes of stimulatory signaling receptors 
expressed on HSCs that bind to cytokines or 
infectious ligands directly participate in the 
infection response: IFN receptors [12-14], TNFα 
receptor [15-17], and TLRs [18-20] (reviewed by 
Goodell’s group [21]). In general, the infection 
or inflammatory signals activate HSCs so that 
HSCs produce more immune effector cells to 
counteract the initial infection. Meanwhile this 
process may chronically lead to accelerated dif-
ferentiation at the expense of loss of HSC 
potency [12]. The aberrant IFN and TNF signal-
ing are associated with myelodysplastic syn-
drome and bone marrow failure [21]. Therefore, 
HSCs are naturally activated to proliferate by 
the “in” signaling to combat infection and 
inflammation. 
Immune inhibitory receptors on stem cells: In 
addition to the above stimulatory receptors, we 
predicted that other immune-related surface 
signaling receptors also regulate the cell fates 
of HSCs. Most recently, we demonstrated that 
inhibitory receptors LILRB2 and PIR-B are 
expressed on the surface of human and mouse 
HSCs respectively [6]. We found that these 
receptors bind to ligands Angiopoietin-like pro-
teins (Angptls) [22-24], to inhibit differentiation 
and support self-renewal of stem cells [6]. 
Multiple types of ligands of LILRB2 and PIR-B 
were identified. In addition to binding to Angptls, 
LILRB2 or PIR-B has been known to bind to 
other ligands including various MHC class I mol-
ecules (MHCI) [25] and myelin inhibitors [26]. 
As reported by Takai’s group, in general an 
inhibitory receptor may bind to its membrane-
bound ligand in trans (in which the ligand is 
expressed on another cells) or in cis (in which 
the ligand is expressed by the same cells that 
express the receptor) [27]. Because Angptls 
are abundantly expressed by many types of 
cells including those from endocrine organs 
[28] and potential BM niche (endothelium and 
adipocytes [23, 28]), and can be induced by 
hypoxia [28], these secreted factors may have 
important direct and indirect effects on the 
activities of HSCs and perhaps other stem cells 
in vivo through possible trans- interaction. To 
support this view, we demonstrated that 
Angptl3 expressed by the bone marrow vascu-
lar cells supports HSC activity [23]. Importantly, 
Angptls are also highly expressed by HSCs per 
se [23, 29]. It is therefore possible that a cis-
interaction between Angptls and LILRB2 occurs 
on HSCs. Future investigations are needed to 
clarify and study the biological significance of 
this cis-interaction.
Similarly, both cis and trans interactions were 
reported to exist between MHCI and LILRB2/
PIR-B. The development of osteoclasts is regu-
lated by cis interaction between PIR-B and 
MHCI as determined by fluorescence reso-
nance energy transfer analysis [30]. The cis 
interaction between PIR-B and MHCI was also 
identified to occur on B cells, dendritic cells, 
and mast cells [31, 32]. Similarly, LILRB2 are 
able to cis interact with MHCI on human baso-
philic leukemia KU812 cells [27]. On the other 
hand, PIR-B on dendritic cells and MHCI on 
CD8+ T cells were found to interact in trans at 
the immunological synapse [31]. Since both 
HSCs and other somatic cells express MHCI [8], 
it will be interesting to test whether the cis and 
trans interactions between inhibitory receptors 
and MHCI exist on HSCs per se and between 
HSCs and regulatory or niche cells. 
While the LILRB/PIR-B receptors were reported 
to suppress activation of differentiated immune 
cells and inhibit neurite outgrowth of neural 
cells [26, 27], they support HSC repopulation 
and inhibit differentiation of leukemia stem 
cells [6]. This result suggests the importance of 
these “inhibitory receptors” in maintenance of 
stemness of stem cells. In contrast to the 
“stimulatory receptors” such as IFN receptors 
or TLRs that activate and induce differentiation 
of HSCs upon infection, LILRB2 or PIR-B may 
respond to niche- or chronic inflammation- pro-
duced Angptls and protects HSCs from exces-
sive activation and exhaustion. We suspect 
that adult stem cells and cancer cells likely 
require both stimulatory receptors and inhibi-
tory receptors to maintain the balance of their 
cell fates.
Interaction between stimulatory receptors and 
inhibitory receptors: The counterregulatory 
roles of immune inhibitory receptors and stimu-
latory receptors expressed on the same cells 
were reported in many studies. While both 
PIR-B (the inhibitory receptor) and c-Kit (the 
HSCs and immunity
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stimulating receptor) are expressed on mast 
cells, their co-ligation inhibited SCF-induced 
mast cell responses [33]. Similarly, c-Kit medi-
ated inflammatory reactions are also counter-
regulated by the inhibitory receptor LILRB4 
[34]. The TCR mediated T cell activation is 
counterregulated by another inhibitory receptor 
LILRB1 [35]. Because LILRB2/PIR-B and c-Kit 
are expressed on the same HSCs [6], it is pos-
sible that the counterregulation between these 
immune inhibitory receptors and stimulatory 
receptors exists on HSCs and is important to 
balance the cell fates of stem cells.
Another example of interaction between 
immune inhibitory receptors and stimulatory 
receptors is the interplay between PIR-B and a 
Toll-like receptor (TLR9) [27]. After the compo-
nents of invaded bacteria or virus bind TLR9 in 
B cells, TLR9-initiated Lyn activation stimulates 
the phosphorylation of PIR-B, leading to 
enhanced SHP-1 recruitment to PIR-B. The 
recruited SHP-1 dephosphorylates the TLR9 
downstream kinase Btk, which then attenuates 
the immune activation that otherwise may pro-
duce overeactive antibodies. This counterregu-
lation of TLR signaling by inhibitory receptor 
PIR-B is important to prevent the potential 
harmful consequence of autoreactive antibod-
ies in immune cells [27]. Again, because both 
PIR-B and several TLRs are expressed on HSCs 
[6, 18, 36], it is to be determined whether these 
two types of receptors have important counter-
regulatory interactions that balance the cell 
fates of stem cells. 
“Out” signaling
HSCs are immune protected by bone marrow 
microenvironment: In vivo, stromal cells and 
other cells form a complex microenvironment 
for HSCs that controls their multiple cell fates, 
including quiescence, apoptosis, and migration 
as well as the cell divisions that lead to forma-
tion either of daughter HSCs or of lineage-com-
mitted progenitors that are capable of limited 
proliferation. Currently, we know of the exis-
tence of several types of cells that form bone 
marrow HSC microenvironment or niches [37]. 
The endosteal HSC niche contains osteoblasts 
as the main supportive cell type for mainte-
nance of hematopoiesis [38, 39]. The vascular 
HSC niche is mainly composed of sinusoidal 
endothelial cells [40]. More recently, it was sug-
gested that these two types of cells may estab-
lish a compound niche [41, 42]. In addition, 
SDF-1 abundant reticular (CAR) cells [43], 
CD146-expressing subendothelial stromal [44], 
Nestin+ mesenchymal stem cells [45], macro-
phages [46, 47], and the sympathetic nervous 
system [48] have also been demonstrated to 
represent components of HSC niches [37]. 
HSCs may indirectly interact with the immune 
system through their microenvironment or 
niche. HSC mobilization can be contributed by 
the suppression of CXC-chemokine ligand 12 
(CXCL12) production by osteoblasts in the bone 
marrow [49], and by complement cascade acti-
vation through granulocyte egress [50]. A 
recent elegant study by Fujisaki et al. using 
high-resolution in vivo imaging demonstrated 
that regulatory T cells (Treg) colocalize with 
HSCs in the endosteal area in the bone marrow 
to protect HSCs from immune attack [2]. IL-10 
produced by these Treg cells plays an essential 
role in this immune protection. This is function-
ally similar to the reported Treg recruitment to 
the cancer microenvironment [51]. These find-
ings suggest that the HSC niche not only speci-
fies an environment to control the cell fates of 
HSCs, but it may also provide an immune-privi-
leged site for HSCs [2]. 
HSCs are capable of regulating their own 
“immune privilege”: While the niche offers pro-
tection for HSCs from immune attack, HSCs are 
capable of migrating in and out of the niche 
[52], which drastically increases the possibility 
that they will interact with the immune system. 
It is evident that HSCs outside of the niche 
apparently are resistant to pathogen infection 
[10, 11]. 
HSCs are capable of protecting themselves 
from innate macrophage phagocytosis [7]. 
CD47, also known as integrin-associated pro-
tein, binds to SIRPa on macrophages and inhib-
its phagocytosis. Weissman’s group showed 
that CD47 is expressed on freshly isolated 
bone marrow HSCs at a relatively low level, 
implying a slim possibility of the potential inter-
action between HSCs and the innate immune 
system at the bone marrow niche. When HSCs 
are activated by potent inflammatory signals 
and mobilize into circulation, the CD47 level is 
dramatically upregulated on the surface of 
HSCs [53]. Similarly, CD47 is also upregulated 
on a variety types of blood cancer and solid 
cancer cells [54]. It was suggested that the 
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increased expression of CD47 on the surface of 
mobilized HSCs and cancer cells protects these 
cells from phagocytosis by macrophages [54].
In addition to evading the potential attack from 
the innate immune system, HSCs are also able 
to protect themselves against the adaptive 
immune system. CD274 (B7-H1 or PD-L1) is a 
member of the B7 family that is expressed on 
dendritic cells, activated immune cells, and 
parenchymal cells under certain condition and 
on cells in immune-privileged sites such as 
eyes and placenta where it inhibits T cell or 
innate activation [55, 56]. CD274 is also selec-
tively expressed by various cellular compo-
nents in the tumor microenvironment, where it 
inhibits tumor-specific T-cell immunity by induc-
ing T cell apoptosis and delaying rejection [55]. 
We recently provided evidence demonstrating 
that HSCs possess the ability to regulate their 
surface expression of CD274 in order to evade 
the rejection by the acquired immune system 
[8]. We showed that CD274, similar to CD47, is 
expressed low on freshly isolated bone marrow 
HSCs in vivo [8]. Surprisingly, after in vitro cul-
ture, HSCs upregulate the surface expression 
of CD274 at least 10-fold, which efficiently 
inhibits host T cell proliferation upon allograft 
transplantation [8]. These observations clearly 
indicate that ex vivo culture significantly modu-
lates the immunogenicity of stem cells. Fiorina 
et al. demonstrated that CD274 is upregulated 
Figure 1. A model of the interplay between HSCs and the immune system. HSCs express surface immune molecules 
for “in” signaling and “out” signaling that directly dialog with the immune system. While the “out” signaling, mediat-
ed by surface molecules such as CD47 and CD274, inhibits attack from the innate immunity and adaptive immunity 
responses, respectively, the stimulatory “in” signaling from infection and inflammation activates HSCs and induces 
differentiation through surface receptors including TLRs, TNFα receptor, IFN receptors, and others. There also may 
exist the inhibitory “in” signaling that decreases differentiation and reserves the stemness of HSCs in response to 
niche or chronic inflammatory cues. In the indicated process A, stimulatory ‘in” signals induces upregulation of the 
“out” signaling by CD274. In the indicated process B, stimulatory receptor signaling activates inhibitory receptor 
signaling, which in turn represses the stimulatory receptor signaling. The co-existence of “in” and “out” signaling 
and their interaction ensure the balance of cell fates of HSCs.
HSCs and immunity
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on mouse splenic Lin-Kit+ hematopoietic cells 
after the treatment of an antagonist of chemo-
kine CXCR4 [57], suggesting that the CD274 
level on phenotypic hematopoietic progenitors 
can be increased upon mobilization. Whether 
the expression of CD274 on primitive and func-
tional HSCs or blood cancer cells can be physi-
ologically regulated in vivo and its biological 
significance warrants further investigation. 
Practically, the future identification of poten-
tially additional immune molecules whose alter-
ations can regulate allograft acceptance will 
enable the complete resolution of the issue of 
immune rejection in allogeneic transplan- 
tation. 
Therefore, in striking contrast to pluripotent 
stem cells, HSCs have modulatable immune 
privilege that can overcome allogeneic immune 
barrier, and HSCs can directly suppress the 
adaptive immunity.
Interaction between “in” and “out” signaling
It is known that the expression of surface 
immune inhibitor CD274 can be induced or 
maintained by proliferating signals [8], espe-
cially interferon‑γ (IFNγ) [55]. This upregulation 
of CD274 expression has been reported to 
occur in various types of cells including cancer 
cells and HSCs [8, 55]. These findings lead us 
to hypothesize that “in” signaling (such as that 
is mediated by IFN receptor) can regulate the 
output of the “out” signaling (such as CD274’s 
immune inhibitory activity) in stem cells. This is 
reasonable because normally HSCs are 
immune privileged in their bone marrow niche; 
only after HSCs sense the immune signals 
through the “in” signaling pathway, they can ini-
tiate responses to enhance their “out” signal-
ing to protect themselves. Further studies are 
needed to investigate the details of mecha-
nisms by which the CD274 expression is upreg-
ulated, and whether other molecules in “out” 
signaling are also controlled by similar 
activities.
In addition to acting as a ligand to inhibit T cell 
responses, CD274 can also function as a recep-
tor to transmit signals into T cells and cancer 
cells [58, 59]. It is possible that this reverse sig-
naling from the “out” signaling may have regu-
latory roles in the balance of self-renewal, dif-
ferentiation, and other cell fates of HSCs.
Model of the interplay between HSCs and the 
immune system
Based on these recent progress and a previous 
model [60], we propose a new model for the 
interaction between HSCs and the immune sys-
tem. Within the niche, HSCs are protected by 
Treg and other niche cells from potential 
immune attack. Outside the niche, HSCs are 
capable of directly interacting with the immune 
system through surface immune molecules for 
“out” signaling and “in” signaling (Figure 1). 
The “out” signaling is mediated by factors such 
as CD47 and CD274 that inhibit attack from the 
innate immunity and adaptive immunity 
responses, respectively. Based on the results 
discussed here, we hypothesize that homeo-
static HSCs express low levels of surface 
immune suppressors, and the levels of these 
suppressors can be induced by stress or 
immune signals. These immune suppressors 
may thus modulate HSC immunogenicity and, 
therefore, contribute to the “immune privilege” 
of HSCs. This regulatable “immune privilege” 
should be advantageous to HSCs as it should 
allow these important stem cells to rapidly 
adjust to altered environmental conditions or 
protect them from excessive immune activa-
tion/inflammation or potential autoimmune 
disorders. 
The stimulatory “in” signaling activates HSCs 
and induces differentiation through surface 
receptors including TLRs, TNFα receptor, IFN 
receptors, and others. The net outcome of the 
activating “in” signaling is to produce immune 
effector cells that counteract the initial infec-
tion. Nevertheless, because adult stem cells 
only have limited division capacity, a chronic 
activating signaling may result in eventual 
decrease of stemness. Therefore the activating 
“in” signaling may be counter-balanced by the 
environmental cues within the stem cell niche 
or from chronic inflammation that activate the 
surface inhibitory receptors (such as LILRB2 
and PIR-B), which inhibit differentiation and 
maintain the quiescence and stemness of 
HSCs. In addition, the stimulating “in” signaling 
may also directly activate the signaling of 
immune inhibitory receptors in the cytosol. The 
co-existence of both types of signals, which 
may regulate each other, ensures a balance of 
cell fates for HSCs. We speculate that an imbal-
ance will lead to either total differentiation 
HSCs and immunity
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(exhaustion, if stimulatory signals dominate) or 
apoptosis (if inhibitory signals dominate). 
As we hypothesize, there may exist interaction 
between the “in” and “out” signaling. It is rea-
sonable to speculate that the “in” signaling that 
is able to sense the immune cues should upreg-
ulate the “out” signaling that protects the stem 
cells from a potential immune surveillance and 
attack. Moreover, this “out” signaling may also 
reversely regulate the cell fates of stem cells 
through the cytosolic signaling domains of the 
immune surface suppressors such as CD274.
The continuing investigation of how stem cells 
interact with the immune system may open up 
a new scientific field - the immunology of stem 
cells. We speculate that a common mechanism 
exists for regulation of immune signals in some 
other types of stem cells. It will be interesting to 
study the immunology of stem cells by investi-
gating the roles of surface immune molecules 
and receptors on pluripotent stem cells, other 
adult stem cells, and cancer stem cells. 
Open questions
The following questions must be addressed to 
provide new insights into the understanding of 
immunology of stem cells:
1) What are the respective roles of trans- and 
cis- interactions between immune surface mol-
ecules and their ligands to control the cell fates 
of stem cells?
2) How do immune inhibitory receptors and 
stimulatory receptors work together to regulate 
the cell fates of stem cells? 
3) How is the expression of immune surface 
molecules regulated in vivo? 
4) What is the connection between the “in” sig-
naling and “out” signaling? Can “in” signaling 
modulate the type and magnitude of “out” sig-
naling and vice versa? Can a surface signaling 
molecule serve both the “in” and “out” 
signaling?
5) What are the expression and functions of 
surface immune molecules and receptors on 
stem cells other than HSCs? 
6) Does the aberrant immune property of stem 
cells cause diseases/cancer?
Acknowledgements
CCZ is the Michael L. Rosenberg Scholar in 
Biomedical Research at UT Southwestern 
Medical Center. Support to CCZ was from NIH 
grant K01 CA 120099, American Society of 
Hematology Junior Faculty Award, American 
Heart Association 09BGIA2230372, DOD 
PR093256, CPRIT RP100402, March of Dimes 
Foundation 5-FY09-146, Robert A. Welch 
Foundation I-1701, and the Gabrielle’s Angel 
Foundation. 
Conflict of interest statement
The author declares no conflicts of interests.
Address correspondence to: Dr. Cheng Cheng 
Zhang, Departments of Physiology and Developm- 
ental Biology, University of Texas Southwestern 
Medical Center, 5323 Harry Hines Boulevard, Dallas, 
Texas 75390, USA. Phone: (214) 6456320; Fax: 
(214) 6481960; E-mail: Alec.Zhang@UTSouthweste- 
rn.edu
References
[1] Bryder D, Rossi DJ and Weissman IL. Hemato-
poietic stem cells: the paradigmatic tissue-
specific stem cell. Am J Pathol 2006; 169: 
338-346.
[2] Fujisaki J, Wu J, Carlson AL, Silberstein L, Pu-
theti P, Larocca R, Gao W, Saito TI, Lo Celso C, 
Tsuyuzaki H, Sato T, Cote D, Sykes M, Strom 
TB, Scadden DT and Lin CP. In vivo imaging of 
Treg cells providing immune privilege to the 
haematopoietic stem-cell niche. Nature 2011; 
474: 216-219.
[3] Swijnenburg RJ, Schrepfer S, Govaert JA, Cao 
F, Ransohoff K, Sheikh AY, Haddad M, Connolly 
AJ, Davis MM, Robbins RC and Wu JC. Immuno-
suppressive therapy mitigates immunological 
rejection of human embryonic stem cell xeno-
grafts. Proc Natl Acad Sci U S A 2008; 105: 
12991-12996.
[4] Zhao T, Zhang ZN, Rong Z and Xu Y. Immunoge-
nicity of induced pluripotent stem cells. Nature 
2011; 474: 212-215.
[5] King KY and Goodell MA. Inflammatory modu-
lation of HSCs: viewing the HSC as a founda-
tion for the immune response. Nat Rev Immu-
nol 2011; 11: 685-692.
[6] Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang 
C, Hyunh H, Kang X, Silvany R, Wan X, Ye J, 
Canto AP, Chen SH, Wang HY, Ward ES and 
Zhang CC. Inhibitory receptors bind ANGPTLs 
HSCs and immunity
225 Am J Blood Res 2012;2(4):219-227
and support blood stem cells and leukaemia 
development. Nature 2012; 485: 656-660.
[7] Chao MP, Weissman IL and Majeti R. The 
CD47-SIRPalpha pathway in cancer immune 
evasion and potential therapeutic implica-
tions. Curr Opin Immunol 2012; 24: 225-232.
[8] Zheng J, Umikawa M, Zhang S, Huynh H, Silva-
ny R, Chen BP, Chen L and Zhang CC. Ex vivo 
expanded hematopoietic stem cells overcome 
the MHC barrier in allogeneic transplantation. 
Cell Stem Cell 2011; 9: 119-130.
[9] Salem HK and Thiemermann C. Mesenchymal 
stromal cells: current understanding and clini-
cal status. Stem Cells 2010; 28: 585-596.
[10] Kolb-Maurer A, Wilhelm M, Weissinger F, 
Brocker EB and Goebel W. Interaction of hu-
man hematopoietic stem cells with bacterial 
pathogens. Blood 2002; 100: 3703-3709.
[11] Hermesh T, Moltedo B, Moran TM and Lopez 
CB. Antiviral instruction of bone marrow leuko-
cytes during respiratory viral infections. Cell 
Host Microbe 2010; 7: 343-353.
[12] Baldridge MT, King KY, Boles NC, Weksberg DC 
and Goodell MA. Quiescent haematopoietic 
stem cells are activated by IFN-gamma in re-
sponse to chronic infection. Nature 2010; 465: 
793-797.
[13] Essers MA, Offner S, Blanco-Bose WE, Waibler 
Z, Kalinke U, Duchosal MA and Trumpp A. IF-
Nalpha activates dormant haematopoietic 
stem cells in vivo. Nature 2009; 458: 904-
908.
[14] Sato T, Onai N, Yoshihara H, Arai F, Suda T and 
Ohteki T. Interferon regulatory factor-2 protects 
quiescent hematopoietic stem cells from type I 
interferon-dependent exhaustion. Nat Med 
2009; 15: 696-700.
[15] Zhang Y, Harada A, Bluethmann H, Wang JB, 
Nakao S, Mukaida N and Matsushima K. Tu-
mor necrosis factor (TNF) is a physiologic regu-
lator of hematopoietic progenitor cells: in-
crease of early hematopoietic progenitor cells 
in TNF receptor p55-deficient mice in vivo and 
potent inhibition of progenitor cell proliferation 
by TNF alpha in vitro. Blood 1995; 86: 2930-
2937.
[16] Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian 
SB, Ferrara JL and Sieff CA. Essential role for 
the p55 tumor necrosis factor receptor in regu-
lating hematopoiesis at a stem cell level. J Exp 
Med 1999; 190: 1493-1504.
[17] Rezzoug F, Huang Y, Tanner MK, Wysoczynski 
M, Schanie CL, Chilton PM, Ratajczak MZ, Fugi-
er-Vivier IJ and Ildstad ST. TNF-alpha is critical 
to facilitate hemopoietic stem cell engraftment 
and function. J Immunol 2008; 180: 49-57.
[18] Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, 
Akira S, Takatsu K and Kincade PW. Toll-like 
receptors on hematopoietic progenitor cells 
stimulate innate immune system replenish-
ment. Immunity 2006; 24: 801-812.
[19] Sioud M, Floisand Y, Forfang L and Lund-Jo-
hansen F. Signaling through toll-like receptor 
7/8 induces the differentiation of human bone 
marrow CD34+ progenitor cells along the my-
eloid lineage. J Mol Biol 2006; 364: 945-954.
[20] Kim JM, Kim NI, Oh YK, Kim YJ, Youn J and Ahn 
MJ. CpG oligodeoxynucleotides induce IL-8 ex-
pression in CD34+ cells via mitogen-activated 
protein kinase-dependent and NF-kappaB-in-
dependent pathways. Int Immunol 2005; 17: 
1525-1531.
[21] Baldridge MT, King KY and Goodell MA. Inflam-
matory signals regulate hematopoietic stem 
cells. Trends Immunol 2011; 32: 57-65.
[22] Zhang CC, Kaba M, Ge G, Xie K, Tong W, Hug C 
and Lodish HF. Angiopoietin-like proteins stim-
ulate ex vivo expansion of hematopoietic stem 
cells. Nat Med 2006; 12: 240-245.
[23] Zheng J, Huynh H, Umikawa M, Silvany R and 
Zhang CC. Angiopoietin-like protein 3 supports 
the activity of hematopoietic stem cells in the 
bone marrow niche. Blood 2011; 117: 470-
479.
[24] Zhang CC, Kaba M, Iizuka S, Huynh H and 
Lodish HF. Angiopoietin-like 5 and IGFBP2 
stimulate ex vivo expansion of human cord 
blood hematopoietic stem cells as assayed by 
NOD/SCID transplantation. Blood 2008; 111: 
3415-3423.
[25] Shiroishi M, Tsumoto K, Amano K, Shirakihara 
Y, Colonna M, Braud VM, Allan DS, Makad-
zange A, Rowland-Jones S, Willcox B, Jones EY, 
van der Merwe PA, Kumagai I and Maenaka K. 
Human inhibitory receptors Ig-like transcript 2 
(ILT2) and ILT4 compete with CD8 for MHC 
class I binding and bind preferentially to HLA-
G. Proc Natl Acad Sci U S A 2003; 100: 8856-
8861.
[26] Atwal JK, Pinkston-Gosse J, Syken J, Stawicki 
S, Wu Y, Shatz C and Tessier-Lavigne M. PirB is 
a functional receptor for myelin inhibitors of 
axonal regeneration. Science 2008; 322: 967-
970.
[27] Takai T, Nakamura A and Endo S. Role of PIR-B 
in autoimmune glomerulonephritis. J Biomed 
Biotechnol 2011; 2011: 275302.
[28] Hato T, Tabata M and Oike Y. The role of angio-
poietin-like proteins in angiogenesis and me-
tabolism. Trends Cardiovasc Med 2008; 18: 
6-14.
[29] Oike Y, Yasunaga K, Ito Y, Matsumoto S, 
Maekawa H, Morisada T, Arai F, Nakagata N, 
Takeya M, Masuho Y and Suda T. Angiopoietin-
related growth factor (AGF) promotes epider-
mal proliferation, remodeling, and regenera-
HSCs and immunity
226 Am J Blood Res 2012;2(4):219-227
tion. Proc Natl Acad Sci U S A 2003; 100: 
9494-9499.
[30] Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito 
Y, Fujimura S, Koga T, Nakamura A, Takayanagi 
H, Itoi E and Takai T. Inhibitory immunoglobu-
lin-like receptors LILRB and PIR-B negatively 
regulate osteoclast development. J Immunol 
2008; 181: 4742-4751.
[31] Endo S, Sakamoto Y, Kobayashi E, Nakamura A 
and Takai T. Regulation of cytotoxic T lympho-
cyte triggering by PIR-B on dendritic cells. Proc 
Natl Acad Sci U S A 2008; 105: 14515-14520.
[32] Masuda A, Nakamura A, Maeda T, Sakamoto Y 
and Takai T. Cis binding between inhibitory re-
ceptors and MHC class I can regulate mast cell 
activation. J Exp Med 2007; 204: 907-920.
[33] Chen CC, Kong DW, Cooper MD and Kubagawa 
H. Mast cell regulation via paired immunoglob-
ulin-like receptor PIR-B. Immunol Res 2002; 
26: 191-197.
[34] Feldweg AM, Friend DS, Zhou JS, Kanaoka Y, 
Daheshia M, Li L, Austen KF and Katz HR. 
gp49B1 suppresses stem cell factor-induced 
mast cell activation-secretion and attendant 
inflammation in vivo. Eur J Immunol 2003; 33: 
2262-2268.
[35] Dietrich J, Cella M and Colonna M. Ig-like tran-
script 2 (ILT2)/leukocyte Ig-like receptor 1 
(LIR1) inhibits TCR signaling and actin cyto-
skeleton reorganization. J Immunol 2001; 
166: 2514-2521.
[36] Yanez A, Murciano C, O’Connor JE, Gozalbo D 
and Gil ML. Candida albicans triggers prolifera-
tion and differentiation of hematopoietic stem 
and progenitor cells by a MyD88-dependent 
signaling. Microbes Infect 2009; 11: 531-535.
[37] Lymperi S, Ferraro F and Scadden DT. The HSC 
niche concept has turned 31. Has our knowl-
edge matured? Ann N Y Acad Sci 2010; 1192: 
12-18.
[38] Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, 
Ross J, Haug J, Johnson T, Feng JQ, Harris S, 
Wiedemann LM, Mishina Y and Li L. Identifica-
tion of the haematopoietic stem cell niche and 
control of the niche size. Nature 2003; 425: 
836-841.
[39] Calvi LM, Adams GB, Weibrecht KW, Weber JM, 
Olson DP, Knight MC, Martin RP, Schipani E, 
Divieti P, Bringhurst FR, Milner LA, Kronenberg 
HM and Scadden DT. Osteoblastic cells regu-
late the haematopoietic stem cell niche. Na-
ture 2003; 425: 841-846.
[40] Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C and 
Morrison SJ. SLAM family receptors distinguish 
hematopoietic stem and progenitor cells and 
reveal endothelial niches for stem cells. Cell 
2005; 121: 1109-1121.
[41] Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, 
Kobayashi M, Kopp HG, Shido K, Petit I, Yanger 
K, James D, Witte L, Zhu Z, Wu Y, Pytowski B, 
Rosenwaks Z, Mittal V, Sato TN and Rafii S. En-
graftment and reconstitution of hematopoiesis 
is dependent on VEGFR2-mediated regenera-
tion of sinusoidal endothelial cells. Cell Stem 
Cell 2009; 4: 263-274.
[42] Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark 
D, Perko K, Alexander R, Schwartz J, Grindley 
JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang 
S, Johnson T, Feldman RA and Li L. Detection 
of functional haematopoietic stem cell niche 
using real-time imaging. Nature 2009; 457: 
97-101.
[43] Sugiyama T, Kohara H, Noda M and Nagasawa 
T. Maintenance of the hematopoietic stem cell 
pool by CXCL12-CXCR4 chemokine signaling in 
bone marrow stromal cell niches. Immunity 
2006; 25: 977-988.
[44] Sacchetti B, Funari A, Michienzi S, Di Cesare S, 
Piersanti S, Saggio I, Tagliafico E, Ferrari S, 
Robey PG, Riminucci M and Bianco P. Self-re-
newing osteoprogenitors in bone marrow sinu-
soids can organize a hematopoietic microenvi-
ronment. Cell 2007; 131: 324-336.
[45] Mendez-Ferrer S, Michurina TV, Ferraro F, Ma-
zloom AR, Macarthur BD, Lira SA, Scadden DT, 
Ma’ayan A, Enikolopov GN and Frenette PS. 
Mesenchymal and haematopoietic stem cells 
form a unique bone marrow niche. Nature 
2010; 466: 829-834.
[46] Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, 
Hashimoto D, Scheiermann C, Battista M, Leb-
oeuf M, Prophete C, van Rooijen N, Tanaka M, 
Merad M and Frenette PS. Bone marrow 
CD169+ macrophages promote the retention 
of hematopoietic stem and progenitor cells in 
the mesenchymal stem cell niche. J Exp Med 
2011; 208: 261-271.
[47] Winkler IG, Sims NA, Pettit AR, Barbier V, Now-
lan B, Helwani F, Poulton IJ, van Rooijen N, Al-
exander KA, Raggatt LJ and Levesque JP. Bone 
marrow macrophages maintain hematopoietic 
stem cell (HSC) niches and their depletion mo-
bilizes HSCs. Blood 2010; 116: 4815-4828.
[48] Katayama Y, Battista M, Kao WM, Hidalgo A, 
Peired AJ, Thomas SA and Frenette PS. Signals 
from the sympathetic nervous system regulate 
hematopoietic stem cell egress from bone 
marrow. Cell 2006; 124: 407-421.
[49] Semerad CL, Christopher MJ, Liu F, Short B, 
Simmons PJ, Winkler I, Levesque JP, Chappel J, 
Ross FP and Link DC. G-CSF potently inhibits 
osteoblast activity and CXCL12 mRNA expres-
sion in the bone marrow. Blood 2005; 106: 
3020-3027.
[50] Ratajczak MZ, Kim CH, Wojakowski W, Janows-
ka-Wieczorek A, Kucia M and Ratajczak J. In-
nate immunity as orchestrator of stem cell mo-
bilization. Leukemia 2010; 24: 1667-1675.
HSCs and immunity
227 Am J Blood Res 2012;2(4):219-227
[51] Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, 
Mottram P, Evdemon-Hogan M, Conejo-Garcia 
JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, 
Daniel B, Gordon A, Myers L, Lackner A, Disis 
ML, Knutson KL, Chen L and Zou W. Specific 
recruitment of regulatory T cells in ovarian car-
cinoma fosters immune privilege and predicts 
reduced survival. Nat Med 2004; 10: 942-
949.
[52] Marquez-Curtis LA, Turner AR, Sridharan S, 
Ratajczak MZ and Janowska-Wieczorek A. The 
ins and outs of hematopoietic stem cells: stud-
ies to improve transplantation outcomes. Stem 
Cell Rev 2011; 7: 590-607.
[53] Jaiswal S, Jamieson CH, Pang WW, Park CY, 
Chao MP, Majeti R, Traver D, van Rooijen N and 
Weissman IL. CD47 is upregulated on circulat-
ing hematopoietic stem cells and leukemia 
cells to avoid phagocytosis. Cell 2009; 138: 
271-285.
[54] Jaiswal S, Chao MP, Majeti R and Weissman IL. 
Macrophages as mediators of tumor immuno-
surveillance. Trends Immunol 2010; 31: 212-
219.
[55] Zou W and Chen L. Inhibitory B7-family mole-
cules in the tumour microenvironment. Nat 
Rev Immunol 2008; 8: 467-477.
[56] Francisco LM, Sage PT and Sharpe AH. The 
PD-1 pathway in tolerance and autoimmunity. 
Immunol Rev 2010; 236: 219-242.
[57] Fiorina P, Jurewicz M, Vergani A, Petrelli A, 
Carvello M, D’Addio F, Godwin JG, Law K, Wu E, 
Tian Z, Thoma G, Kovarik J, La Rosa S, Capella 
C, Rodig S, Zerwes HG, Sayegh MH and Abdi R. 
Targeting the CXCR4-CXCL12 axis mobilizes 
autologous hematopoietic stem cells and pro-
longs islet allograft survival via programmed 
death ligand 1. J Immunol 2011; 186: 121-
131.
[58] Dong H, Strome SE, Matteson EL, Moder KG, 
Flies DB, Zhu G, Tamura H, Driscoll CL and 
Chen L. Costimulating aberrant T cell respons-
es by B7-H1 autoantibodies in rheumatoid ar-
thritis. J Clin Invest 2003; 111: 363-370.
[59] Azuma T, Yao S, Zhu G, Flies AS, Flies SJ and 
Chen L. B7-H1 is a ubiquitous antiapoptotic re-
ceptor on cancer cells. Blood 2008; 111: 
3635-3643.
[60] Zheng J, Song C and Zhang CC. A new chapter: 
hematopoietic stem cells are direct players in 
immunity. Cell Biosci 2011; 1: 33.
